ArticleAmerican journal of hematology2026
Defining a Subgroup of Myelodysplastic Syndrome Patients With Very Poor-Risk Cytogenetics Demonstrating a Relatively More Favorable Outcome After Allogeneic Hematopoietic Cell Transplantation.
Xavier Poiré et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.